DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Otitis media — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOtitis media maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for otitis media is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 1 (NR3C1) — NR3C1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7KW7 · 3.57 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Otitis media is the most common bacterial infection among children, accounting for as many as 30 million office visits annually in the United States, with management costs exceeding 3 billion dollars per year. A 2003 review found that medical and surgical therapy are of limited utility in the management of acute and recurrent acute otitis media, and that antibiotics and steroids are of limited value in the treatment of chronic middle ear effusion. The same review noted that delayed management of effusion may not adversely affect development in children, and that many practitioners still struggle with diagnosis and often recommend intervention inappropriately. Bacterial biofilms may account for persistence of middle ear disease, and there is increasing evidence that heredity and reflux are risk factors.
Earlier work from 1994 emphasised that successful treatment depends on accurate definitions and classifications of types of otitis media, and that an understanding of the otitis media continuum assists in management. That review directed attention to newer concepts regarding pathobiology and pharmacotherapy, but did not report any specific drug efficacy data or survival outcomes. A separate 1994 review noted that significant basic and clinical research continues in an attempt to limit untoward effects of this common pathologic process, but again provided no quantitative results from trials.
No concrete numbers on response rates, survival, or sample sizes are reported in any of these abstracts. The 2003 review states plainly that vaccination for pneumococcus may alter the serotypes responsible for otitis media and that vaccine candidates for other middle ear pathogens are under investigation, but no trial results are given. What is still missing are adequately powered randomised trials that test specific drugs or vaccines against placebo or standard care, with clearly defined diagnostic criteria and patient stratification by age, effusion type, and recurrence history. Funding for such trials and for training primary care providers in accurate diagnosis remains insufficient.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Otolaryngology & Head & Neck Surgery · 2003 · 28 citations
Otitis media: concepts and controversies
AbstractPURPOSE OF REVIEW: Otitis media is the most common bacterial infection among children, accounting for as many as 30 million office visits annually. Proper treatment has become critical as offending pathogens become increasingly resistant to antibiotics and the cost of managing the disorder has exceeded 3 billion dollars per year. However, data suggest that many practitioners still struggle with the diagnosis of otitis media and often recommend medical and surgical intervention inappropriately. This article presents recent advances in the otitis media literature and an evidence-based approach to its management. RECENT FINDINGS: Recent investigations have resulted in the following findings: (1) bacterial biofilms may account for the persistence of middle ear disease; (2) there is increasing evidence that heredity and reflux are risk factors for otitis media; (3) primary care providers may be receiving poor otitis media training, leading to inadequate diagnostic skills; (4) medical and surgical therapy are of limited utility in the management of acute and recurrent acute otitis media; (5) antibiotics and steroids are of limited value in the treatment of chronic middle ear effusion; (6) delayed management of effusion may not adversely affect development in children; (7) vaccination for pneumococcus may alter the serotypes responsible for otitis media; and (8) vaccine candidates for other middle ear pathogens are under investigation. SUMMARY: Management of otitis media is constantly evolving, based on research from a variety of medical subspecialties. It is incumbent on the otolaryngologist and primary care providers treating otitis media to keep pace with and synthesize these findings into a rational approach to treatment.
AbstractTreatment of otitis media has changed over time as the disease has become better understood and as clinical experience and technology have expanded and grown. Successful treatment depends on accurate definitions and classifications of types of otitis media. An awareness of the pathogenic and pathologic correlates of otitis media enhances accurate diagnosis and improves the results of treatment. An understanding of the otitis media continuum also assists in management. On the basis of studies largely emanating from the University of Minnesota's Otitis Media Pathogenesis Research Program, we here highlight definitions, classifications, and diagnosis of the otitis medias, and medical treatments of these various clinical and pathologic entities and their sequelae.
Current Opinion in Otolaryngology & Head & Neck Surgery · 1994 · 0 citations
Otitis media
AbstractOtitis media as a clinical entity has received significant press recently both in the lay and professional literature. Despite recent debate regarding management protocols, significant basic and clinical research continues in an attempt to limit the untoward effects of this very common pathologic process. This review directs attention to newer concepts regarding both the pathobiology of otitis media and the pharmacotherapy available for management.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
